C4 Therapeutics

C4 Therapeutics

  • Founded: 2016
  • Location: Watertown, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Multiple myeloma, NHL
  • Drug types: ONC
  • Lead product: CFT7455
  • Product link: https://c4therapeutics.com/our-pipeline/
  • Funding: $209M IPO Oct 2020; $170M Jun 2020; $73M Jan 2016



job board

Short description:

Ubiquitin-proteasome system based therapeutics, protein degradation

Drug notes:

CFT8634 Clin1 synovial sarcoma, solid tumors; CFT1946 Clin1/Clin2 multiple cancers; CFT8919 Clin0 NSCLC; 3 undisclosed programs RD/Clin0 oncology

Long description:

C4 Therapeutics is developing therapies to control cellular protein levels through protein degradation. Ubiquitination is the first step of a versatile, widely-conserved and modular system used by cells to degrade and recycle proteins. C4T’s approach utilizes this unique innate machinery of the cell for precision degradation of disease-causing proteins. The control of protein levels is achieved by a small molecule drug called a degrader. Degraders have high selectivity for their protein target and are not destroyed in the process providing high potency to degrade many copies of the protein. C4T is using their Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform to discover and synthesize degraders initially beginning with oncology targets.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com